beta blockers and semaglutide 'have no effect' | & tirzepatide boost HF outcomes | DCBs make little impact | Big news for Medtronic Afraid of heart failure? Don't
Description
Through lowering blood sugar levels, semgalutide reduces symptoms of high blood sugar that are associated with diabetes, including frequent urination, thirst, diabetic retinopathy, nerve damage, vision changes and cardiovascular risk
doi: 10.1111/dom.13361
These innovations aim to improve patient compliance and provide more flexible treatment options, making it easier for patients to manage their health
The FDA recommends discontinuing GLP-1 medications at least two months before a planned pregnancy
the difference is lower cost and personalized dosing
Hasta 16% de prdida de peso Los pacientes pierden hasta un 16% de su peso corporal con el tratamiento y seguimiento adecuado
